ReviewSurgical oncology2017
The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms.
Review in Surgical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 77 citations in OpenAlex.
- A Feline Milk-DrivedMicroorganisms · 2026Article
- The gut microbiota in colorectal cancer: role in cytokine regulation, intestinal immune barrier dysfunction.Frontiers in oncology · 2026Review
- The Prophylactic Protection ofMicroorganisms · 2025Article
- Analysis of garlic intake on atrophic gastritis risk in different infectious states of Helicobacter pylori in a case-control study.Scientific reports · 2025Article
- Insights into the Interaction BetweenJournal of personalized medicine · 2025Review
- Gut microbiota in gastric cancer: from pathogenesis to precision medicine.Frontiers in microbiology · 2025Review
- The Prophylactic Protection of Salmonella Typhimurium Infection by Lentilactobacillus buchneri GX0328-6 in Mice.Probiotics and antimicrobial proteins · 2024Article
- Association between being breastfed in infancy and adult colorectal cancer risk among Japanese men and women.Scientific reports · 2024Article
- Gut microbiota as a biomarker and modulator of anti-tumor immunotherapy outcomes.Frontiers in immunology · 2024Review
- Postbiotics in colorectal cancer: intervention mechanisms and perspectives.Frontiers in microbiology · 2024Review
- Article
- The microbiome and rise of early-onset cancers: knowledge gaps and research opportunities.Gut microbes · 2023Review
- Microbiota Effect on Trimethylamine N-Oxide Production: From Cancer to Fitness-A Practical Preventing Recommendation and Therapies.Nutrients · 2023Review
- Exploring the gut microbiota: lifestyle choices, disease associations, and personal genomics.Frontiers in nutrition · 2023Review
- Biomarkers to Detect Early-Stage Colorectal Cancer.Biomedicines · 2022Review
- Dysbiotic microbes and how to find them: a review of microbiome profiling in prostate cancer.Journal of experimental & clinical cancer research : CR · 2022Review
- Chronic Kidney Disease and Cancer: Inter-Relationships and Mechanisms.Frontiers in cell and developmental biology · 2022Review
- Associations of Changes in Intestinal Flora and Inflammatory Factors with Prognosis of Patients with Esophageal Cancer.Journal of healthcare engineering · 2022Article
- Emulating interactions between microorganisms and tumor microenvironment to develop cancer theranostics.Theranostics · 2022Review
- Qingchang Wenzhong Decoction Prevents the Occurrence of Intestinal Tumors by Regulating Intestinal Microbiota and Gasdermin E.Frontiers in physiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 2 countries.
Funding
Abstract
More than 100 trillion microorganisms inhabit the human intestinal tract and play important roles in health conditions and diseases, including cancer. Accumulating evidence demonstrates that specific bacteria and bacterial dysbiosis in the gastrointestinal tract can potentiate the development and progression of gastrointestinal tract neoplasms by damaging DNA, activating oncogenic signaling pathways, producing tumor-promoting metabolites such as secondary bile acids, and suppressing antitumor immunity. Other bacterial species have been shown to produce short-chain fatty acids such as butyrate, which can suppress inflammation and carcinogenesis in the gastrointestinal tract. Consistent with these lines of evidence, clinical studies using metagenomic analyses have shown associations of specific bacteria and bacterial dysbiosis with gastrointestinal tract cancers, including esophageal, gastric, and colorectal cancers. Emerging data demonstrate that intestinal bacteria can modulate the efficacy of cancer chemotherapies and novel targeted immunotherapies such as anti-CTLA4 and anti-CD274 therapies, the process of absorption, and the occurrence of complications after gastrointestinal surgery. A better understanding of the mechanisms by which the gut microbiota influence tumor development and progression in the intestine would provide opportunities to develop new prevention and treatment strategies for patients with gastrointestinal tract cancers by targeting the intestinal microflora.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.